# 119-hr-7871: MVP Act

119-hr-7871, MVP Act, is a 119th Congress bill sponsored by Rep. Guthrie, Brett [R-KY-2] (R-KY); status introduced; PRIA reads it as touching household money (as of 2026-09-21).

- Canonical: https://policyrisk.com/legislation/119-hr-7871
- As of: 2026-09-21
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Bill: 119-hr-7871
- Congress: 119
- Title: MVP Act
- Status: introduced
- Introduced: 2026-03-09
- Sponsor: Rep. Guthrie, Brett [R-KY-2] (R-KY)
- Cosponsors: 17
- Policy area: Health
- Touches household money: yes
- Last recorded action: 2026-09-21

## Summary

**This bill would codify and expand Medicaid value-based purchasing arrangements, letting states and drug makers use multiple “best price” tiers and bundled-sales rules to tie payments to patient outcomes.** It would also change how Medicaid and Medicare calculate drug prices and add a new Anti-Kickback Statute safe harbor for payments to States under these arrangements. - States and Medicaid programs would get clearer authority to run VBPs, use multiple best-price points for the same drug strength, and treat those deals as bundled sales. The bill directs guidance on inpatient drugs and allows inter-State fund transfers so patients treated outside their home State can be treated as if in their home State. - Drug manufacturers would have to include outcome-triggered rebates, refunds, and free goods from VBPs when reporting Average Manufacturer Price for Medicaid. The bill adds special rules for installment payments that treat the full aggregate price as paid in the first installment for reporting, and it excludes VBP remuneration from Medicare average sales price when a multiple best-price election is used. HHS must issue implementing rules within 180 days. - The bill creates an Anti-Kickback Statute safe harbor for VBPs that provide remuneration to States and requires HHS’s Inspector General to publish implementing rules within 180 days. It also orders a Government Accountability Office study, with a final report due June 30, 2029, on access to transformative therapies, socioeconomic disparities, interactions with the Medicaid drug rebate program and 340B, Part B prices, and potential long-term state savings.

## Cosponsors (17)

- Rep. Auchincloss, Jake [D-MA-4] (D-MA), 2026-03-09T00:00:00.000Z
- Rep. Miller-Meeks, Mariannette [R-IA-1] (R-IA), 2026-03-09T00:00:00.000Z
- Rep. Joyce, John [R-PA-13] (R-PA), 2026-03-09T00:00:00.000Z
- Rep. Peters, Scott H. [D-CA-50] (D-CA), 2026-03-09T00:00:00.000Z
- Rep. Davis, Donald G. [D-NC-1] (D-NC), 2026-03-09T00:00:00.000Z
- Rep. Mullin, Kevin [D-CA-15] (D-CA), 2026-05-11T00:00:00.000Z
- Rep. Ivey, Glenn [D-MD-4] (D-MD), 2026-05-11T00:00:00.000Z
- Rep. Van Duyne, Beth [R-TX-24] (R-TX), 2026-05-11T00:00:00.000Z
- Rep. Carter, Earl L. "Buddy" [R-GA-1] (R-GA), 2026-05-12T00:00:00.000Z
- Rep. Dunn, Neal P. [R-FL-2] (R-FL), 2026-05-12T00:00:00.000Z
- Rep. Cammack, Kat [R-FL-3] (R-FL), 2026-05-20T00:00:00.000Z
- Rep. Lieu, Ted [D-CA-36] (D-CA), 2026-05-26T00:00:00.000Z
- Rep. Kelly, Mike [R-PA-16] (R-PA), 2026-06-08T00:00:00.000Z
- Rep. Meuser, Daniel [R-PA-9] (R-PA), 2026-06-08T00:00:00.000Z
- Rep. Balderson, Troy [R-OH-12] (R-OH), 2026-06-08T00:00:00.000Z
- Rep. Bilirakis, Gus M. [R-FL-12] (R-FL), 2026-06-30T00:00:00.000Z
- Rep. Wilson, Joe [R-SC-2] (R-SC), 2026-07-21T00:00:00.000Z

## Provisions PRIA read

- Guidance on inpatient Medicaid drug deals: benefit, low. If enacted, HHS would issue guidance to State Medicaid agencies within 180 days on using VBPs for drugs given with inpatient hospital care when those drugs are paid for separately. The guidance would explain how multiple States can agree with each other and with manufacturers to transfer funds. Thi…
- Changes to Medicaid and Medicare drug pricing: mixed, high. If enacted, this would change how drug makers and programs report prices and rebates for value-based purchasing (VBP) drug deals. A manufacturer could report multiple "best price" points for the same drug only if it offers the VBP to all States. For drugs sold under a VBP, Medicaid price calculatio…
- New safe harbor for Medicaid VBP payments: mixed, medium. If enacted, this would add an exception to the federal Anti-Kickback law for payments a drug maker (or third party for the maker) gives a State under a value-based purchasing arrangement when a patient fails to meet outcome goals. The exception would cover VBP payments under a State Medicaid plan o…

## Related bills

- 119-hr-9877: Health Equity and Accountability Act of 2026
- 119-hr-909: Crime Victims Fund Stabilization Act of 2025
- 119-hr-842: Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act
- 119-hr-9250: Great American Outdoors Act 250
- 119-hr-3514: Improving Seniors’ Timely Access to Care Act of 2025
- 119-hr-1502: North Platte Canteen Congressional Gold Medal Act

## Sources
- [119-hr-7871 on Congress.gov](https://www.congress.gov/bill/119th-congress/house-bill/7871)

## Related
- [119-hr-9877: Health Equity and Accountability Act of 2026](https://policyrisk.com/legislation/119-hr-9877)
- [119-hr-909: Crime Victims Fund Stabilization Act of 2025](https://policyrisk.com/legislation/119-hr-909)
- [119-hr-842: Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage A…](https://policyrisk.com/legislation/119-hr-842)
- [119-hr-9250: Great American Outdoors Act 250](https://policyrisk.com/legislation/119-hr-9250)
- [119-hr-3514: Improving Seniors’ Timely Access to Care Act of 2025](https://policyrisk.com/legislation/119-hr-3514)
- [119-hr-1502: North Platte Canteen Congressional Gold Medal Act](https://policyrisk.com/legislation/119-hr-1502)
- [All bills in Congress](https://policyrisk.com/legislation)

Source: PRIA, https://policyrisk.com/legislation/119-hr-7871 (as of 2026-09-21).